Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

4.5K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
4.5K
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

196
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
196
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.0K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.0K
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.6K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.6K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

651
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
651
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

181
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
181

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A proteome-wide atlas of humoral immunity to <i>Mycobacterium tuberculosis</i> across the spectrum of disease.

Frontiers in immunology·2026
Same author

Deep learning approach for probabilistic pulmonary function estimation from chest X-ray and peak expiratory flow rate.

Communications medicine·2026
Same author

Interventions to reduce the impact of post-tuberculosis lung disease: a scoping review of the literature.

BMC pulmonary medicine·2026
Same author

Differences in tuberculosis prevalence by sex in low- and middle-income countries over 1993-2025: A systematic review and meta-analysis.

PLoS medicine·2026
Same author

Migration-linked TB epidemics: How TB elimination in high-income countries depends on the success of TB control in high-burden settings.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Safety of short-course weekly rifapentine and isoniazid (3HP) for TB preventive treatment at conception and during first trimester in women living with HIV: a secondary analysis of WHIP3TB trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Pulmonary fibrosis in chILD: bridging the gap.

The Lancet. Respiratory medicine·2026
Same journal

Heterogeneity of severe asthma in Europe: a SHARP-er view.

The Lancet. Respiratory medicine·2026
Same journal

Severe asthma and remission prospects in Europe (SHARP): insights from a multicentre observational study based on the European Severe Asthma Registry.

The Lancet. Respiratory medicine·2026
Same journal

Prevalence and disease trajectories of pulmonary fibrosis of childhood interstitial lung disease: a register-based, multicentre observational study.

The Lancet. Respiratory medicine·2026
Same journal

Correction to Lancet Respir Med 2026; published online May 28. https://doi.org/10.1016/S2213-2600(26)00160-8.

The Lancet. Respiratory medicine·2026
Same journal

Trump Administration sparks furore and resignations over fruit-flavoured vape authorisations.

The Lancet. Respiratory medicine·2026
See all related articles

Related Experiment Video

Updated: Feb 12, 2026

Imaging Mycobacterium tuberculosis in Mice with Reporter Enzyme Fluorescence
10:06

Imaging Mycobacterium tuberculosis in Mice with Reporter Enzyme Fluorescence

Published on: February 26, 2018

7.8K

Pan-tuberculosis regimens: an argument for

Robert S Wallis1, Ted Cohen2, Nicolas A Menzies3

  • 1Aurum Institute, Johannesburg, South Africa.

The Lancet. Respiratory Medicine
|March 30, 2018
PubMed
Summary

No abstract available in PubMed .

More Related Videos

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

19.7K
Separation and Fractionation of Culture Filtrate Proteins (CFPs) from Mycobacterium tuberculosis
08:48

Separation and Fractionation of Culture Filtrate Proteins (CFPs) from Mycobacterium tuberculosis

Published on: July 11, 2025

641

Related Experiment Videos

Last Updated: Feb 12, 2026

Imaging Mycobacterium tuberculosis in Mice with Reporter Enzyme Fluorescence
10:06

Imaging Mycobacterium tuberculosis in Mice with Reporter Enzyme Fluorescence

Published on: February 26, 2018

7.8K
The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

19.7K
Separation and Fractionation of Culture Filtrate Proteins (CFPs) from Mycobacterium tuberculosis
08:48

Separation and Fractionation of Culture Filtrate Proteins (CFPs) from Mycobacterium tuberculosis

Published on: July 11, 2025

641